The healthcare sectors are recognizing the value of innovative and effective strategies to address the challenges of managing specialty drugs, which treat complex, chronic or rare conditions and require special administration or handling. As a strategy to control the costs associated with managing a complex patient population, the market is turning to value-based contracting, which links reimbursement or payment for aproduct to positive clinical outcomes. These trends have paved the way for an increase in limited distribution drugs (LDDs), or therapies only made available to a small number of specialty pharmacies, to give manufacturers greater oversight and control over the quality of patient care and support. Specialty drugs are the future of medicine, but they require high-touch care coordination and concerted follow-up to ensure patients remain adherent and can manage potential side effects to realize the full value of therapy.

Learn more about your ad choices. Visit megaphone.fm/adchoices